Age and acute myeloid leukemia - PubMed (original) (raw)
Clinical Trial
Age and acute myeloid leukemia
Frederick R Appelbaum et al. Blood. 2006.
Abstract
We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature of AML changes with age. Older study patients with AML presented with poorer performance status, lower white blood cell counts, and a lower percentage of marrow blasts. Multidrug resistance was found in 33% of AMLs in patients younger than age 56 compared with 57% in patients older than 75. The percentage of patients with favorable cytogenetics dropped from 17% in those younger than age 56 to 4% in those older than 75. In contrast, the proportion of patients with unfavorable cytogenetics increased from 35% in those younger than age 56 to 51% in patients older than 75. Particularly striking were the increases in abnormalities of chromosomes 5, 7, and 17 among the elderly. The increased incidence of unfavorable cytogenetics contributed to their poorer outcome, and, within each cytogenetic risk group, treatment outcome deteriorated markedly with age. Finally, the combination of a poor performance status and advanced age identified a group of patients with a very high likelihood of dying within 30 days of initiating induction therapy. The distinct biology and clinical responses seen argue for age-specific assessments when evaluating therapies for AML.
Figures
Figure 1.
Southwest Oncology Group Leukemia Committee percentage of patients in cytogenetic risk groups by age category. The percentage includes only patients with a known cytogenetic risk group.
Figure 2.
OS by age for patients with unfavorable risk cytogenetics. Patients younger than 56 years (n = 108) had a median survival of 11 months, patients aged 56 to 65 years (n = 70) had a median survival of 5 months, and patients aged 66 to 75 years (n = 78) had a median survival of 4 months, as did the 27 patients older than 75 years.
Figure 3.
OS by age for patients with intermediate risk cytogenetics. Patients younger than 56 years (n = 149) had a median survival of 26 months, patients aged 56 to 65 years (n = 101) had a median survival of 12 months, patients aged 66 to 75 years (n = 110) had a median survival of 8 months, and patients older than 75 years (n = 24) had a median survival of 7 months.
Figure 4.
OS by age for patients with favorable risk cytogenetics. The median overall survival for patients younger than age 56 (n = 51) and those aged 56 to 65 (n = 10) has not been reached, while the median survival for those older than age 65 (n = 12) was 12 months.
Similar articles
- Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, Dworzak M, Perglerová K, Zemanova Z, Tchinda J, Bradtke J, Thiede C, Haferlach C. Creutzig U, et al. Cancer. 2016 Dec 15;122(24):3821-3830. doi: 10.1002/cncr.30220. Epub 2016 Aug 16. Cancer. 2016. PMID: 27529519 - Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia.
Namratha Udupa MS, Babu KG, Suresh Babu MC, Lakshmaiah KC, Lokanatha D, Jacob AL, Lokesh KN, Rajeev LK, Rudresh AH, Devi L. Namratha Udupa MS, et al. J Cancer Res Ther. 2020 Jan-Mar;16(1):18-22. doi: 10.4103/jcrt.JCRT_1162_16. J Cancer Res Ther. 2020. PMID: 32362604 - Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?
Foran JM. Foran JM. Best Pract Res Clin Haematol. 2017 Dec;30(4):306-311. doi: 10.1016/j.beha.2017.09.008. Epub 2017 Oct 7. Best Pract Res Clin Haematol. 2017. PMID: 29156200 Review.
Cited by
- Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis.
Jiao N, Shi L, Wang S, Sun Y, Bai Y, Zhang D. Jiao N, et al. BMC Cancer. 2024 Oct 13;24(1):1271. doi: 10.1186/s12885-024-13000-3. BMC Cancer. 2024. PMID: 39396935 Free PMC article. - Case report: Successful combination of CLL1 CAR-T therapy and hematopoietic stem cell transplantation in a 73-year-old patient diagnosed with refractory acute myeloid leukemia.
Zhao Y, Wang H, Zhang Y, Zhang Y, Zhang X, Zhao M, Liu J, Guo S, Zhao M. Zhao Y, et al. Front Immunol. 2024 Sep 17;15:1454614. doi: 10.3389/fimmu.2024.1454614. eCollection 2024. Front Immunol. 2024. PMID: 39355240 Free PMC article. - Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia.
Wang T, Cui S, Lyu C, Wang Z, Li Z, Han C, Liu W, Wang Y, Xu R. Wang T, et al. Heliyon. 2024 Aug 20;10(17):e36155. doi: 10.1016/j.heliyon.2024.e36155. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263156 Free PMC article. - CXCL12 chemokine dimer signaling modulates acute myelogenous leukemia cell migration through altered receptor internalization.
Drouillard D, Halyko M, Cinquegrani E, McAllister D, Peterson FC, Marchese A, Dwinell MB. Drouillard D, et al. bioRxiv [Preprint]. 2024 Aug 27:2024.08.26.609725. doi: 10.1101/2024.08.26.609725. bioRxiv. 2024. PMID: 39253415 Free PMC article. Preprint. - Ferroptosis-Related Gene Signature for Prognosis Prediction in Acute Myeloid Leukemia and Potential Therapeutic Options.
Hong Y, Liu Q, Xin C, Hu H, Zhuang Z, Ge H, Shen Y, Zhao Y, Zhou Y, Ye B, Wu D. Hong Y, et al. Int J Gen Med. 2024 Sep 4;17:3837-3853. doi: 10.2147/IJGM.S460164. eCollection 2024. Int J Gen Med. 2024. PMID: 39246807 Free PMC article.
References
- Leith CP, Chir B, Kopecky KJ, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89: 3323-3329. - PubMed
- Leith CP, Kopecky KJ, Chen I-M, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. a Southwest Oncology Group study. Blood. 1999;94: 1086-1099. - PubMed
- Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339: 1649-1656. - PubMed
- Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96: 4075-4083. - PubMed
- Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood. 1998;91: 3607-3615. - PubMed
Publication types
MeSH terms
Grants and funding
- CA12213/CA/NCI NIH HHS/United States
- CA20319/CA/NCI NIH HHS/United States
- CA46282/CA/NCI NIH HHS/United States
- CA46368/CA/NCI NIH HHS/United States
- CA32102/CA/NCI NIH HHS/United States
- CA38926/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical